Navigate this market better. Subscribe for FREE stock alerts and information.

Wednesday, October 22, 2014

BRIEF-Ipsen and Lexicon sign licensing and commercialization agreement for telotristat etiprate, (NASDAQ: LXRX)

Ipsen SA : * Lexicon Pharmaceuticals and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate* Ipsen to commercialize telotristat etiprate outside of North America and Japan* Lexicon retains sole rights to commercialize telotristat etiprate in United States, Canada and Japan Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20;

Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Shares of LXRX traded higher by 2.27% or $0.03/share to $1.35. In the past year, the shares have traded as low as $1.04 and as high as $2.57. On average, 852225 shares of LXRX exchange hands on a given day and today's volume is recorded at 1123831.